Oncobiologics (OTLK)
(Delayed Data from NSDQ)
$8.43 USD
+0.24 (2.93%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $8.42 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 5/20/24 |
---|---|
Current Quarter | -0.88 |
EPS Last Quarter | -0.80 |
Last EPS Surprise | 20.00% |
ABR | 1.14 |
Earnings ESP
|
0.00% |
---|---|
Current Year | -2.99 |
Next Year | -1.84 |
EPS (TTM) | -4.00 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (9/2024) |
Next Year (9/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | NA | NA | 1.43M | 14.11M |
# of Estimates | NA | NA | 1 | 4 |
High Estimate | NA | NA | 1.43M | 31.70M |
Low Estimate | NA | NA | 1.43M | 3.80M |
Year ago Sales | 0.00M | 0.00M | NA | 1.43M |
Year over Year Growth Est. | NA | NA | NA | 886.57% |
Earnings Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (9/2024) |
Next Year (9/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -0.88 | -0.86 | -2.99 | -1.84 |
# of Estimates | 3 | 3 | 4 | 4 |
Most Recent Consensus | -0.95 | -1.09 | -3.42 | -0.85 |
High Estimate | -0.42 | -0.64 | -1.97 | -0.85 |
Low Estimate | -1.28 | -1.09 | -3.77 | -2.29 |
Year ago EPS | -0.60 | -1.60 | -4.80 | -2.99 |
Year over Year Growth Est. | -46.67% | 46.25% | 37.71% | 38.46% |
Agreement - Estimate Revisions
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (9/2024) |
Next Year (9/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 0 | 0 | 0 | 0 |
Up Last 60 Days | 2 | 1 | 2 | 2 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 0 | 0 | 0 | 0 |
Down Last 60 Days | 1 | 2 | 1 | 1 |
Magnitude - Consensus Estimate Trend
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (9/2024) |
Next Year (9/2025) |
|
---|---|---|---|---|
Current | -0.88 | -0.86 | -2.99 | -1.84 |
7 Days Ago | -0.88 | -0.86 | -2.99 | -1.84 |
30 Days Ago | -0.88 | -0.86 | -2.99 | -1.84 |
60 Days Ago | -1.00 | -1.13 | -3.76 | -2.75 |
90 Days Ago | -1.00 | -1.07 | -3.92 | -2.33 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (9/2024) |
Next Year (9/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -0.88 | -0.86 | -2.99 | -1.84 |
Zacks Consensus Estimate | -0.88 | -0.86 | -2.99 | -1.84 |
Earnings ESP | 0.00% | 0.00% | 0.00% | 0.00% |
Surprise - Reported Earnings History
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Quarter Ending (3/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -0.80 | -1.00 | -1.60 | -0.60 | NA |
Estimate | -1.00 | -1.00 | -0.80 | -1.20 | NA |
Difference | 0.20 | 0.00 | -0.80 | 0.60 | 0.00 |
Surprise | 20.00% | 0.00% | -100.00% | 50.00% | -7.50% |
Quarterly Estimates By Analyst
Zacks Premium Subscription Required Learn more
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more